Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/33577
Título: | Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients |
Autor(es): | Valadão, Marcus Braggio, Danielle Santos, Anna Flávia Pimenta-Inada, Haynna Kimie Linhares, Eduardo Gonçalves, Rinaldo Romano, Sérgio Vilhena, Bruno Small, Isabele Cubero, Daniel Cruz, Felipe Oliveira, Antônio Talvane Martinho, Olga Reis, R. M. Guimarães, Denise Peixoto Ferreira, Carlos Gil |
Palavras-chave: | GIST IGF Imatinib mesylate Metastatic Prediction Response |
Data: | 2012 |
Editora: | Elsevier 1 |
Revista: | The Journal of Surgical Research |
Resumo(s): | Imatinib therapy has undoubtedly contributed to the treatment of metastatic gastrointestinal stromal (GIST) tumors that were previously untreatable. However, disease progression during treatment with tyrosine kinase inhibitors remains an issue in clinical practice not fully explained by KIT and PDGFRA mutation status. We investigated the role of three important signaling molecules (insulin-like growth factor 1 receptor [IGF1R], protein kinase C-? [PKC?], and Raf kinase inhibitor protein [RKIP]) that have been implicated in GIST pathogenesis as potential biomarkers for prediction of response to imatinib treatment. We retrospectively reviewed 76 patients with metastatic GIST submitted to imatinib treatment between 2002 and 2007, and analyzed 63 of them. Insulin-like growth factor 1, total PKC?, phosphorylated PKC?, and RKIP immunohistochemical expression were correlated with objective response to imatinib treatment and progression-free and overall survival. Median follow-up was 31.2 mo (95% confidence interval, 26.3-36.1 mo). There was a statistically significant association between IGF1R expression and type of response to imatinib treatment (P = 0.05)-that is, higher IGF1R expression was related to lower objective response. However, IGF1R higher expression did not affect progression-free and overall survival. Insulin-like growth factor 1, but not PKC? and RKIP, emerges as a potential biomarker for prediction of response to imatinib treatment in metastatic GISTs. Validation studies are warranted. |
Tipo: | Artigo |
URI: | https://hdl.handle.net/1822/33577 |
DOI: | 10.1016/j.jss.2012.03.031 |
ISSN: | 0022-4804 |
Versão da editora: | http://www.sciencedirect.com/science/article/pii/S0022480412002429 |
Arbitragem científica: | yes |
Acesso: | Acesso restrito UMinho |
Aparece nas coleções: | ICVS - Artigos em revistas internacionais / Papers in international journals |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
valadao m_j surgl res 2012.pdf Acesso restrito! | 745,49 kB | Adobe PDF | Ver/Abrir |